Brief: Kairos Pharma Ltd. Announces Completed Enrollment of the Safety Arm of Its Phase 2 Clinical Trial of ENV105 in Metastatic, Castration-Resistant Prostate Cancer
31/03/2025 12:13
March 31 (Reuters) - Kairos Pharma Ltd KAPA.A: KAIROS PHARMA LTD. ANNOUNCES COMPLETED ENROLLMENT OF THE SAFETY ARM OF ITS PHASE 2 CLINICAL TRIAL OF ENV105 IN METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER KAIROS PHARMA LTD - SAFETY AND EFFICACY DATA READOUT EXPECTED IN FIRST HALF OF 2025 Source text: ID:nBw5qrQnva Further company coverage: KAPA.A ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kairos Pharma
See all newsBrief: Kairos Pharma Announces Signing Of Binding Strategic Asset Acquisition Of Exclusive Worldwide Rights To Cl-273 From Orbimed And Torrey Pines Investment-Backed Celyn Therapeutics
Brief: Kairos Pharma Announces Signing Of Term Sheet For Strategic Asset Acquisition
Brief: Kairos Pharma To Present Positive Safety And Efficacy Data From Phase 2 Prostate Cancer Trial At Esmo 2025
Brief: Kairos Pharma Reports Positive Interim Phase 2 Data For ENV105 In Advanced Prostate Cancer, PFS Over One Year
Brief: Kairos Pharma Announces Virtual KOL Event To Provide Perspectives On ENV105 Interim Efficacy Results In Advanced Prostate Cancer